STIM · Neuronetics, Inc.
$3.03
+0.02 (+0.66%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Therefore, substantial doubt exists about the Company's ability to continue as a going concern. Actions within the Company's control to meet its minimum revenue covenant include improvements to its revenue cycle management, introducing new treatment options at its clinic locations and pursuing new strategies within its NeuroStar business to accelerate sales growth and optimize its product mix. The Company's ability to meet its liquidity needs, including meeting future revenue and liquidity covenants, is dependent on growth in existing and acquired product and service lines and the realization of synergies related to its acquisition of Greenbrook. However, at this time, these actions do not fully mitigate the risk related to compliance with the revenue covenant for the March 31, 2027 period. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 11, 2026
Market Cap
$230.88M
Shares
76.20M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.03
Open$3.10
Day$3.02–3.15
52W close$1.18–3.46
Avg vol 30d2.3M
Short int6.7M · 8.8% float · 6.5d
Short vol42%
Last earningsAug 11, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 14, 2026
Est · unconfirmed
· in 9 wks
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$155.10M
Trailing 12 months
Net income (TTM)
−$30.42M
Trailing 12 months
Revenue growth YoY
+9.1%
Year over year
Operating margin
-14.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.5%
Year over year · more shares
Price change (1Y)
-12.8%
Trailing year
Short interest
8.8%
Latest settlement · 6.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+76%
above
Price vs 50-day avg
+26%
above
RSI (14)
61
neutral
MACD trend
Negative
52-week position
81%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+109%
trailing
YTD return
+120%
this year
Relative strength
+91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +16 funds added
Insider flow
Accumulating
Net +$106.5K over 90 days · 0% sells
Short interest
Falling
8.75% of float · ▼ -17.2% MoM · 6.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+31%
Y/Y
Gross margin
137%
expanding
EPS growth
+57%
Y/Y
Balance sheet
$37.7M
net debt
Quant / Vol
risk profile
Volatility
116%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 11, 2026
Total revenue
· for the year
$160M – $164M
Gross margin
· for the year
48% – 50%
OPEX excluding share-based compensation
· for the year
$91M – $96M
Prior guidance
period ended
· from the 8-K filed Aug 12, 2024
Total worldwide revenue
· third quarter of 2024
$18.5M – $19.5M
Total worldwide revenue
· full year 2024
$78M – $80M
Total operating expenses
· full year 2024
$78M – $80M
Guided vs delivered
· last 4 settled
Total worldwide revenue
third quarter of 2024
guided $18.5M – $19.5M
$18.53M
In line
Total worldwide revenue
full year 2024
guided $78M – $80M
$74.89M
Miss −5.2%
Total revenue
full year 2021
guided $53.3M – $54.3M
$55.31M
Beat +2.8%
Revenue
second quarter of 2021
guided $14M – $15M
$14.2M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+76%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
61
Neutral
MACD trend
Negative
Bearish
52-week position
81%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +16 funds added
Insider flow
Accumulating
Net +$106.5K over 90 days · 0% sells
Short interest
Falling
8.75% of float · ▼ -17.2% MoM · 6.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $3 · 81%
Range high $3
vs 200-day avg +76%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STIM
this stock
Neuronetics, Inc.
|
$230.88M | +119.6% | +30.5% | — | 8.8% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STIM | +11.4% | +0.0% | +109.0% | +6.7% | +119.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +12.6% | +1.8% | +91.1% | +7.1% | +107.5% |